GlaxoSmithKline’s product to help protect against cervical cancer, called Cervarix, shows that it works against five common cervical cancer-causing viruses. There are two common types of cervical cancer, and three less common types.

Cervarix offered “11 to 16 percent extra protection against cervical cancer over and above the protection afforded by efficacy against the two most common types alone.” Research indicates that this is the first time protection has been shown against “pre-cancerous lesions not containing the two most common virus types.”
This is good news for cervical cancer research. Cervarix is approved in 90 countries, but has …read more

GlaxoSmithKline has won a contract with the UK’s NHS to supply its cervical cancer vaccine,
Cervarix.
The battle to supply a vaccine against cervical cancer for use across Britain has been won by GlaxoSmithKline (GSK).
Cervarix, the GSK vaccine, will be given to girls aged between 12 and 13, starting in September this year, and should prevent about 70 per cent of cervical cancers — saving 400 lives a year when the effect is fully felt.
Read more from The UK Times Online.
Let’s wait and see what Merck (maker of the other cervical cancer vaccine Gardasil) has to say about this.

Speaking of cervical cancer vaccines, there are two notables: Gardasil by Merck which was approved by the FDA earlier this year and Cervarix by GlaxoSmithKline which is expected to be approved by the FDA later this year (but already approved in Australia).

Regarding these HPV vaccines that will protect women against cervical cancer, the CDC recommends that the vaccine should be routinely given to girls at 11-12 years of age – the stage before young girls are more likely to become sexually active.
Now there is a new project that will evaluate and monitor the effectiveness of these vaccines.
The said project -funded …read more

Cervarix™ is the cervical cancer vaccine candidate of GlaxoSmithKline which have been previously known to protect from human papillomavirus (HPV) types 16 and 18.
Now, an Australian study of under 150 Perth women included in a major international research at the Telethon Institute for Child Health Research proved that the new Cervarix vaccine provides broader protection against cervical cancer because it also demonstrated additional protection against infectious from other strains of HPV that account for another 10 percent of cervical cancers.
According to co-author Dr Rachel Skinner, who headed the Perth trial:
“We have found through this study that this vaccine is extremely …read more